Busting 6 myths about CT screening for lung cancer

Like many hospitals, Memorial Sloan Kettering (MSK) launched a Lung Cancer Screening Program to provide low-dose lung CT screening to current and former smokers who are at high risk for developing lung cancer.

While there are many programs like these, patients who would benefit most from it are not getting screened, possibly due to myths and misconceptions surrounding it.

Thoracic surgeon Bernard Park and radiologist Michelle Ginsberg from MSK are setting the record straight and putting several myths to rest, in hopes to get more patients in. 

Myths

  • If I quit smoking, I am no longer at risk and don't need to undergo lung cancer screening.
  • Lung cancer screening is still considered experiemental and is not part of standard care.
  • Lung cancer screening has a high rate of false positives, leading to many unnecessary procedures.
  • The scans used in lung cancer screening expose you to dangerous radiation.
  • If lung cancer is found, it will be too late for effective treatment.
  • Lung cancer screening is time consuming.

The lung cancer screening program states that depending on a patients smoking history or current smoking habits, certain guidelines should be followed for lung cancer screening. Pateints who are worried about how long the low-dose CT scan takes, medical staff should remind them that it takes less than five minutes. And like MSK, if your hospital offers screening and consultation combined into a single appointment, patients should be reminded of that benefit.

Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.

Around the web

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?